Additionally, fulvestrant treatment further increased tumor cell killing induced by MCL1 si-NPs in LTED-selected cells lines (Fig. 6c), suggesting that Mcl-1 targeting in combination with second-line fulvestrant treatment may be a clinical strategy to increase tumor cell death in ERα+ breast cancer patients. The gene discussed is ESR1; the disease is neoplasm.